The South African Nuclear Energy Corporation (Necsa) was established as a public company by the Republic of South Africa Nuclear Energy Act in 1999 and is wholly owned by the State. The name is correctly indicated above, although the sequence of letters in the acronym may be taken as suggesting that the name should be the "Nuclear Energy Corporation of South Africa".
South African Nuclear Energy Corporation Wikipedia
Necsa replaced the country's Atomic Energy Corporation. Apart from several ancillary functions, the main functions of Necsa are to undertake and promote research and development in the field of nuclear energy and related technologies; to process and store nuclear material and other restricted material; and to co-ordinate with other organisations in matters falling within these spheres. Apart from its main operations at Pelindaba, Necsa also operates the Vaalputs radioactive waste-disposal facility. The Corporation also serves the State's other nuclear institutional obligations. The chief executive officer of Necsa is Mr. Phumzile Tshelane since 1 September 2012.
Necsa is organisationally divided into a commercial group, Pelindaba Technology (PT), which conducts business in a variety of products and markets and another group, Pelindaba Nuclear Institute (PNI), which is concerned with statutory functions, R&D, support and facility operations. Pelindaba Technology (PT) is a portfolio of businesses of which Nuclear Technology Products (NTP) is a division and serves the international markets for radiation-based technology and products. Also, the Uranium Enrichment Corporation of South Africa, Ltd. (UCOR) which operated a facility at Valindaba (known as the 'Y' plant) to produce HEU.
Necsa employs some 1,400 people in diverse areas such as physics, engineering, chemistry and electronics. With changes in the country’s positioning on nuclear involvement and South Africa’s re-entry into world markets in 1990, a decision was taken to focus the organisation on commercially driven projects. Today, Necsa supplies a wide range of products and services to South African and foreign market sectors with the SAFARI-1 reactor as the cornerstone of the commercial isotope production programme. This research reactor at Pelindaba, SAFARI-1 produces medical isotopes such as Molybdenum-99 which are sold globally by the NTP. The NTP Radioisotopes Group had sales of 1.222 billion ZAR (€75M) in 2016.
The 20 MW research reactor SAFARI-1 was initially used for high level nuclear physics research programmes and was commissioned in 1965. In the 1970s and 1980s, amid reduced output due to embargo of international fuel supply, the focus of activities at Pelindaba was on the exploitation of South Africa’s uranium resources through the successful design, construction and commissioning of commercial uranium hexafluoride, uranium enrichment, and nuclear fuel assembly production facilities. In 1993 focus shifted to commercial operations and over the following years typical output in creased back to 20MW. Since 2009 the reactor has operated solely on low enriched uranium fuel.